期刊
JOURNAL OF CLINICAL MEDICINE
卷 11, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/jcm11061484
关键词
age-related macular degeneration; genomics; non-coding RNAs; biomarkers; therapeutics
资金
- Macular Degeneration Foundation, Inc. (Henderson, NV, USA)
- Carl Marshall Reeves & Mildred Almen Reeves Foundation, Inc. (Fenton, MO, USA)
- NIH/NEI [1K08EY031800-01]
Age-related macular degeneration (AMD) is a leading cause of blindness in the aging population. Specific prognostic tools and effective therapies for intermediate and advanced stages of AMD are needed. Recent clinical trials have shown promising results with anti-C5 and anti-C3 agents in slowing the growth of advanced AMD, but they may increase the incidence of wet AMD. Further research on the role of non-coding RNAs (ncRNAs) in AMD is crucial for developing biomarkers and therapeutic targets.
Age-related macular degeneration (AMD) is a progressive neurodegenerative disease that is the world's leading cause of blindness in the aging population. Although the clinical stages and forms of AMD have been elucidated, more specific prognostic tools are required to determine when patients with early and intermediate AMD will progress into the advanced stages of AMD. Another challenge in the field has been the appropriate development of therapies for intermediate AMD and advanced atrophic AMD. After numerous negative clinical trials, an anti-C5 agent and anti-C3 agent have recently shown promising results in phase 3 clinical trials, in terms of slowing the growth of geographic atrophy, an advanced form of AMD. Interestingly, both drugs appear to be associated with an increased incidence of wet AMD, another advanced form of the disease, and will require frequent intravitreal injections. Certainly, there remains a need for other therapeutic agents with the potential to prevent progression to advanced stages of the disease. Investigation of the role and clinical utility of non-coding RNAs (ncRNAs) is a major advancement in biology that has only been minimally applied to AMD. In the following review, we discuss the clinical relevance of ncRNAs in AMD as both biomarkers and therapeutic targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据